Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Argent Trust Co

Argent Trust Co boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 4.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,067 shares of the biopharmaceutical company’s stock after purchasing an additional 91 shares during the quarter. Argent Trust Co’s holdings in Regeneron Pharmaceuticals were worth $1,701,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $697,296,000. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 37.3% during the 2nd quarter. Capital International Investors now owns 2,956,615 shares of the biopharmaceutical company’s stock worth $2,124,326,000 after buying an additional 803,143 shares during the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 57,848.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after buying an additional 581,379 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $116,520,000. Finally, Virginia Retirement Systems ET AL acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $83,318,000. 84.15% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $817.30, for a total value of $81,730.00. Following the completion of the sale, the director now directly owns 18,447 shares of the company’s stock, valued at approximately $15,076,733.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $817.30, for a total value of $81,730.00. Following the sale, the director now directly owns 18,447 shares of the company’s stock, valued at $15,076,733.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,911 shares of company stock worth $8,884,428. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.3 %

NASDAQ:REGN opened at $945.18 on Monday. The stock has a 50-day simple moving average of $886.91 and a 200-day simple moving average of $834.78. The stock has a market cap of $102.98 billion, a P/E ratio of 27.20, a P/E/G ratio of 2.86 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $973.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.74 and a current ratio of 6.41.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the prior year, the business posted $10.96 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 39.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on REGN shares. Truist Financial reissued a “buy” rating and set a $1,045.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, December 18th. Cantor Fitzgerald reissued a “neutral” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, January 9th. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a report on Wednesday, December 6th. Jefferies Financial Group lifted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $937.00 and gave the company a “buy” rating in a report on Tuesday, November 28th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $929.74.

Get Our Latest Report on REGN

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.